Stifel Upgrades Repare Therapeutics (RPTX)
Nasdaq Fintel reports that on June 9, 2023, Stifel upgraded their outlook for Repare Therapeutics (NASDAQ:RPTX) from Hold to Buy .
Analyst Price Forecast Suggests 128.19% Upside
As of June 2, 2023, the average one-year price target for Repare Therapeutics is 27.20. The forecasts range from a low of 11.11 to a high of $51.45. The average price target represents an increase of 128.19% from its latest reported closing price of 11.92.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Repare Therapeutics is 31MM, a decrease of 77.48%. The projected annual non-GAAP EPS is -3.06.
What is the Fund Sentiment?
There are 120 funds or institutions reporting positions in Repare Therapeutics. This is a decrease of 2 owner(s) or 1.64% in the last quarter. Average portfolio weight of all funds dedicated to RPTX is 0.27%, a decrease of 34.99%. Total shares owned by institutions decreased in the last three months by 0.75% to 35,862K shares. The put/call ratio of RPTX is 0.15, indicating a bullish outlook.